India to United States: Amiodarone Export Trade Route

To import finished pharmaceutical formulations containing Amiodarone into the United States, compliance with the U.S. Food and Drug Administration (FDA) regulations is mandatory. The primary requirements include:

1. Drug Establishment Registration and Listing: Foreign manufacturers must register their establishments with the FDA and list all drug products intended for commercial distribution in the U.S. This registration must be renewed annually.

2. Approved Drug Applications: Each Amiodarone formulation must have an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) before importation. The application should be submitted in the Common Technical Document (CTD) or electronic CTD (eCTD) format. Approval timelines vary but typically range from 10 to 12 months for NDAs and 8 to 10 months for ANDAs.

3. Good Manufacturing Practice (GMP) Compliance: Indian manufacturing facilities producing Amiodarone formulations must comply with FDA's GMP standards. This involves routine inspections by the FDA to ensure adherence to quality standards.

4. Import Entry Procedures: Importers must file an entry notice and an entry bond with U.S. Customs and Border Protection (CBP) pending FDA's decision on the product's admissibility.

Indian exporters of Amiodarone formulations must adhere to the FDA's GMP regulations, which encompass:

• Facility Registration: All foreign drug establishments must register with the FDA and list their drug products intended for U.S. distribution.

• GMP Inspections: The FDA conducts inspections of foreign manufacturing facilities to ensure compliance with GMP standards.

As of March 2026, specific details regarding the current approval status of Indian facilities manufacturing Amiodarone formulations are not publicly disclosed. However, the FDA maintains a database of registered establishments and their compliance status.

In December 2024, the FDA inspected an Indian pharmaceutical manufacturer and identified significant GMP violations, including unsanitary conditions in production and storage areas. The inspection revealed live rodents and birds in storage areas, animal feces and feathers on walls and floors, and mold-like deposits on ceilings and walls near production equipment. These findings led to regulatory actions against the manufacturer.

Between October 2024 and March 2026, the FDA implemented several regulatory measures affecting pharmaceutical imports:

• Import Alert 66-72: Issued in October 2024, this alert allows for the detention without physical examination of misbranded drugs and marketed new drugs without approved applications.

• Import Alert 68-09: Updated in December 2024, this alert pertains to the detention without physical examination of new bulk animal drug substances.

These regulatory actions underscore the FDA's commitment to ensuring that imported pharmaceutical products meet established safety and efficacy standards.

In 2024, the U.S. antiarrhythmic drugs market was valued at approximately $369.7 million, with projections indicating growth to $512.9 million by 2030, reflecting a compound annual growth rate (CAGR) of 5.6% from 2025 to 2030. This growth is driven by factors such as the aging population, increased prevalence of cardiovascular diseases, and advancements in healthcare infrastructure. Amiodarone, as a key component of this market, plays a significant role in meeting the therapeutic needs associated with these conditions.

The United States sources a substantial portion of its amiodarone formulations through imports, with India being a primary supplier. In the most recent data, India exported finished pharmaceutical formulations containing amiodarone worth $56.2 million to the United States, accounting for 75.4% of India's total amiodarone formulation exports valued at $74.6 million. This underscores the critical role of Indian manufacturers in the U.S. supply chain for this medication.

Pharmaceutical products under HS code 30049099, including amiodarone formulations, are imported into the United States duty-free under the MFN status. There are no additional import duties, value-added taxes (VAT), or goods and services taxes (GST) imposed on these products. Currently, there is no Free Trade Agreement (FTA) between India and the United States that specifically affects pharmaceutical tariffs. Additionally, there are no anti-dumping duties imposed on amiodarone formulations imported from India.

India is the predominant supplier of amiodarone formulations to the United States, with exports totaling $56.2 million, representing 75.4% of India's total amiodarone formulation exports. Other countries also contribute to the U.S. supply, but specific data on their export values and market shares are not provided in the available information.

Indian manufacturers are known for offering competitive pricing for pharmaceutical formulations, including amiodarone, compared to manufacturers from regions such as China and the European Union. This cost advantage, combined with the established quality standards of Indian pharmaceutical products, reinforces India's strong position in the U.S. market for amiodarone formulations.

India is a leading global producer of generic pharmaceuticals, supplying a significant portion of the world's finished dosage forms, including formulations containing Amiodarone. As of November 2024, India had 376 facilities registered with the U.S. Food and Drug Administration (FDA), comprising 200 active pharmaceutical ingredient (API) facilities and 134 finished dosage form (FDF) facilities. This extensive infrastructure enables large-scale production of Amiodarone tablets and other formulations. The country's cost-effective manufacturing processes, combined with a substantial number of WHO-GMP and FDA-approved facilities, ensure high-quality production standards. In the fiscal year 2024-2025, India exported $56.2 million worth of finished pharmaceutical formulations containing Amiodarone to the United States, accounting for 75.4% of its total Amiodarone formulation exports.

When comparing Amiodarone formulation exports, India offers competitive advantages over China and the European Union (EU). India's cost-effective manufacturing processes result in lower price per unit for finished dosage forms. The quality of Indian pharmaceutical products is well-regarded, with numerous FDA-approved facilities ensuring compliance with stringent regulatory standards. In contrast, while the EU produces high-quality branded generics, their higher production costs often lead to more expensive products. China, primarily known for API production, has a smaller share in finished dosage forms and faces challenges related to quality perception and regulatory acceptance in the United States. India's established track record of supply reliability further solidifies its position as a preferred source for Amiodarone formulations.

The India-United States supply chain for Amiodarone formulations is robust and reliable. India's manufacturing capacity for finished dosage forms is substantial, supported by a large number of FDA-approved facilities. The country's packaging and cold chain capabilities are well-developed, ensuring the integrity of pharmaceutical products during transit. There have been no significant supply disruptions reported in recent years, and Indian manufacturers maintain a strong regulatory compliance track record. Top Indian formulation manufacturers have been expanding their capacities to meet growing global demand, indicating no current capacity constraints.

For United States buyers sourcing Amiodarone formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs may vary among suppliers; negotiate terms that align with your demand forecasts and inventory management strategies.

• Payment Terms: Standard payment terms in India-United States pharmaceutical trade often include letters of credit or advance payments; establish clear agreements to avoid financial discrepancies.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet FDA and WHO-GMP standards.

• Regulatory Compliance: Stay updated on regulatory changes in both India and the United States to ensure continuous compliance and avoid potential trade barriers.

By adhering to this comprehensive approach, United States buyers can effectively qualify Indian suppliers of Amiodarone formulations, ensuring compliance with regulatory standards and the delivery of high-quality pharmaceutical products.